Clinical efficacy and safety of entecavir combined with peginterferon α-2a in the treatment of chronic hepatitis B
10.13699/j.cnki.1001-6821.2015.23.001
- VernacularTitle:恩替卡韦联合聚乙二醇干扰素α－2a治疗慢性乙型病毒性肝炎的临床疗效及安全性
- Author:
Shang-Yan NIE
1
;
Lei ZHAO
;
Hui-Yu MA
;
Huan-Huan SONG
;
Min WANG
;
Li-Fei LU
Author Information
1. 邯郸市中心医院 肝病科
- Keywords:
entecavir;
chronic hepatitis B;
hepatitis Beantigen positive;
peginterferon α-2 a
- From:
The Chinese Journal of Clinical Pharmacology
2015;(23):2281-2283
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the clinical efficacy and safety of entecavir joint peginterferon α-2 a in the treatment of chronic hepatitis B.Methods The 80 cases of chronic hepatitis B patients were randomly divided into control group ( n =40 ) and treatment group ( n =40 ) . Patients in control group were given peginterferonα-2a 0.5 mL, once a week.Patients in treatment group were plused with oral entecavir 0.5 mg on the basis of control group, once a day.A course of treatment was a month in two groups, 12 courses of treatment. Respectively in the treatment of 3, 6, 12 months and 6 months after treatment, the hepatitis B virus ( HBV) DNA negative rate and alanine aminotransferase ( ALT) normalization rate of two groups were tested.After treatment, the clinical efficacy and incidence of adverse drug reactions of the two groups were compared.Results After treatment, the total effective rate of treatment group was significantly higher than that of control group ( 92.50% vs 67.50%, P<0.05).The treatment of 3, 6, 12 months and 6 months after treatment,the HBV DNA negative rate and ALT normalization rate of treatment group were significantly higher than those of control group (P<0.05).Adverse drug reactions in two groups had no significant difference (P>0.05).Conclusion Entecavir combined with peginterferonα-2a in the treatment of chronic hepati-tis B had distinct clinical efficacy and good safety.
